Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AZD4512

Antibody-drug conjugate · Cytotoxic, directed at CD22 · developed by ASTRAZENECA

Phase 1/2 Most advanced trial
AZN Developer

What is AZD4512?

AZD4512 is an antibody-drug conjugate that binds CD22, a B-lineage transmembrane phosphoglycoprotein expressed on mature and malignant B cells. After internalization and linker cleavage, it releases a DNA topoisomerase I inhibitor that causes DNA damage and apoptosis in tumor cells. It is being studied in B-cell non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
CD22, DNA topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at CD22
Pathways
DNA replication inhibition, DNA damage response, apoptosis
Therapy area
Oncology
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

Conditions studied

B-cell Non-Hodgkin Lymphoma

Other drugs acting on CD22

More from ASTRAZENECA

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind AZD4512

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.